ARQ 092

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Proteus Syndrome

Conditions

Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders

Trial Timeline

— → —

NCT ID

NCT03317366

About ARQ 092

ARQ 092 is a pre-clinical stage product being developed by Merck for Proteus Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03317366. Target conditions include Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03317366	Pre-clinical	Completed	—	—	Proteus Syndrome
NCT01473095	Phase 1	Completed	Nov 1, 2011	Aug 7, 2017	Solid Tumor

Competing Products

2 competing products in Proteus Syndrome

See all competitors

Product	Company	Stage	Hype Score
Miransertib	Merck	Phase 2	39
Miransertib	Merck	Phase 1/2	24